cms glp 1 coverage 📣The Bridge program is scheduled to start on July 1! Are you ready? The Medicare GLP-1 Bridge program marks a historic shift by expanding access to obesity medications for eligible Medicare CMS Update: What to Know

Key findings from published and presented studies include: In a phase 2 obesity trial, higherdose retatrutide produced average weight loss of around 22.824.2% over 48 weeks in people with obesity. In participants with type 2 diabetes, retatrutide achieved substantial weight loss and marked improvements in blood sugar and cardiometabolic markers, though average percentage weight loss was somewhat lower than in nondiabetic obesity cohorts. Early studies also reported significant reductions in liver fat and visceral adipose tissue, with a high proportion of participants with fatty liver disease showing resolution of hepatic steatosis at higher doses. These results have led several reviews to describe retatrutide as a potential game changer in obesity pharmacotherapy, representing the first GLP1/GIP/glucagon triple agonist with robust human data. Popular coverage has highlighted phase 3 data suggesting average weight losses approaching 29% of body weight in some cohorts (roughly 71 pounds), which is about double typical results with semaglutide over comparable periods

I didnt know much about microneedling before, but I was really pleasantly surprised by this microneedle patch

We treat it as part of long-term, whole-person medical care

There is already evidence (sourced from channel checks at CES and my own experience at JPM Healthcare) that the impact of ML, DL, and Generative AI is spreading to microvertical areas such as health, medicine, agriculture, entertainment, and beauty